10-Q: Milestone Pharmaceuticals Faces Setback with Complete Response Letter for Etripamil NDA

Milestone Pharmaceuticals received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for CARDAMYST (etripamil) nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT), citing CMC issues.

Summary

• Milestone Pharmaceuticals received a Complete Response Letter (CRL) from the FDA for its New Drug Application (NDA) for CARDAMYST (etripamil) nasal spray for the treatment of PSVT.
• The FDA's CRL highlighted two key Chemistry, Manufacturing and Controls (CMC) issues: additional information on nitrosamine impurities and a required inspection at a facility listed in the NDA.
• The company plans to request a Type A meeting with the FDA to discuss the issues raised in the CRL.
• Milestone Pharmaceuticals reported a net loss of $20.8 million for the three months ended March 31, 2025, compared to a net loss of $10.4 million for the same period in 2024.
• As of March 31, 2025, the company had cash, cash equivalents, and short-term investments of $56.0 million.
• The company expects its existing cash and cash equivalents and short-term investments to be sufficient to fund its operations for at least the next 12 months.
• Milestone is also developing etripamil nasal spray for the treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR) and has finalized a Phase 3 study protocol, but is delaying enrollment due to the CRL.
• The company manages its operations as a single operating segment focused on the development and commercialization of cardiovascular medicines.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the CRL from the FDA, which introduces uncertainty and delays. However, the company has sufficient cash to operate for the next 12 months and is working to address the FDA's concerns.

Positives

• The FDA did not raise any concerns regarding clinical safety or efficacy in the Complete Response Letter.
• The company expects its existing cash and cash equivalents and short-term investments to be sufficient to fund its operations for at least the next 12 months.
• Milestone has temporarily paused the ramping up of operational expenditures related to launch and continues to maintain the capability of launching quickly following the approval of CARDAMYST by the FDA.
• Milestone is also developing etripamil nasal spray for the treatment of atrial fibrillation with rapid ventricular rate (AFib-RVR) and has finalized a Phase 3 study protocol.

Negatives

• Milestone Pharmaceuticals received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for CARDAMYST (etripamil) nasal spray for the treatment of PSVT.
• The FDA's CRL highlighted two key Chemistry, Manufacturing and Controls (CMC) issues: additional information on nitrosamine impurities and a required inspection at a facility listed in the NDA.
• Milestone Pharmaceuticals reported a net loss of $20.8 million for the three months ended March 31, 2025, compared to a net loss of $10.4 million for the same period in 2024.
• The company is delaying enrollment of the Phase 3 AFib-RVR study due to the CRL received on the NDA for etripamil in PSVT.

Risks

• The company's future success is substantially dependent on the successful clinical development and regulatory approval of etripamil.
• International trade policies, including tariffs, sanctions and trade barriers may adversely affect the company's business, financial condition, results of operations and prospects.
• Disruptions at the FDA and other government agencies caused by layoffs, funding shortages or global health concerns could negatively impact the company's business.

Future Outlook

The company expects its existing cash and cash equivalents and short-term investments to be sufficient to fund its operations for at least the next 12 months. The company plans to address the issues raised in the CRL and resubmit the NDA for etripamil. Milestone continues to maintain the capability of launching quickly following the approval of CARDAMYST by the FDA.

Industry Context

Milestone Pharmaceuticals is focused on developing and commercializing cardiovascular medicines, specifically etripamil, for conditions like PSVT and AFib-RVR. The company aims to provide a self-administered treatment option for patients experiencing acute episodes, potentially reducing the need for emergency department visits. The market for these conditions is significant, with millions of Americans affected and substantial healthcare costs associated with current treatment approaches.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• However, the document does mention that drugs approved for the treatment of attacks of PSVT include adenosine, verapamil, and diltiazem, with all being administered intravenously under medical supervision, usually in the emergency department.
• The document also mentions that other oral drugs are sometimes used to treat attacks in a concept called pill in the pocket, but those drugs have never been proven effective or safe and are not approved for this use.

Stakeholder Impact

• Shareholders may experience a negative impact due to the delay in potential approval and commercialization of etripamil.
• Employees may experience uncertainty due to the delay in potential approval and commercialization of etripamil.
• Patients may experience a delay in access to a potential new treatment option for PSVT.

Next Steps

• The company plans to request a Type A meeting with the FDA to discuss the issues raised in the CRL.
• The company will need to address the FDA's concerns regarding nitrosamine impurities and ensure the manufacturing facility passes FDA inspection.
• The company will then resubmit the NDA in response to the CRL.
• The company plans to continue development of etripamil for AFib-RVR, but is delaying enrollment of the Phase 3 study due to the CRL.

Key Dates

Keywords

etripamil, CARDAMYST, PSVT, AFib-RVR, FDA, Complete Response Letter, Milestone Pharmaceuticals, clinical trials, NDA, regulatory approval